Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tepilamide Fumarate as a Novel Potentiator of Virus-Based Therapy.
Alwithenani A, Arulanandam R, Wong B, Spinelli MM, Chen A, Maznyi G, Gilchrist VH, Alain T, Diallo JS. Alwithenani A, et al. Among authors: maznyi g. Viruses. 2024 Jun 5;16(6):920. doi: 10.3390/v16060920. Viruses. 2024. PMID: 38932212 Free PMC article.
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy.
Wong B, Bergeron A, Maznyi G, Ng K, Jirovec A, Birdi HK, Serrano D, Spinelli M, Thomson M, Taha Z, Alwithenani A, Chen A, Lorimer I, Vanderhyden B, Arulanandam R, Diallo JS. Wong B, et al. Among authors: maznyi g. Mol Ther. 2023 Nov 1;31(11):3176-3192. doi: 10.1016/j.ymthe.2023.09.017. Epub 2023 Sep 27. Mol Ther. 2023. PMID: 37766429 Free PMC article.
Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines.
Alluqmani N, Jirovec A, Taha Z, Varette O, Chen A, Serrano D, Maznyi G, Khan S, Forbes NE, Arulanandam R, Auer RC, Diallo JS. Alluqmani N, et al. Among authors: maznyi g. Front Immunol. 2022 Nov 28;13:1032356. doi: 10.3389/fimmu.2022.1032356. eCollection 2022. Front Immunol. 2022. PMID: 36532027 Free PMC article.
Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screen.
Taha Z, Arulanandam R, Maznyi G, Godbout E, Carter-Timofte ME, Kurmasheva N, Reinert LS, Chen A, Crupi MJF, Boulton S, Laroche G, Phan A, Rezaei R, Alluqmani N, Jirovec A, Acal A, Fekete EEF, Singaravelu R, Petryk J, Idorn M, Potts KG, Todesco H, John C, Mahoney DJ, Ilkow CS, Giguère P, Alain T, Côté M, Paludan SR, Olagnier D, Bell JC, Azad T, Diallo JS. Taha Z, et al. Among authors: maznyi g. Mol Ther. 2022 Sep 7;30(9):2998-3016. doi: 10.1016/j.ymthe.2022.04.025. Epub 2022 May 6. Mol Ther. 2022. PMID: 35526097 Free PMC article.
Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern.
Carter-Timofte ME, Arulanandam R, Kurmasheva N, Fu K, Laroche G, Taha Z, van der Horst D, Cassin L, van der Sluis RM, Palermo E, Di Carlo D, Jacobs D, Maznyi G, Azad T, Singaravelu R, Ren F, Hansen AL, Idorn M, Holm CK, Jakobsen MR, van Grevenynghe J, Hiscott J, Paludan SR, Bell JC, Seguin J, Sabourin LA, Côté M, Diallo JS, Alain T, Olagnier D. Carter-Timofte ME, et al. Among authors: maznyi g. ACS Infect Dis. 2021 Nov 12;7(11):3034-3051. doi: 10.1021/acsinfecdis.1c00278. Epub 2021 Oct 18. ACS Infect Dis. 2021. PMID: 34658235